• 1
    Valentini G. The assessment of the patient with systemic sclerosis. Autoimmun Rev 2003; 2: 3706.
  • 2
    Medsger TA Jr. Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003; 29: 25573.
  • 3
    Mayes MD. Scleroderma epidemiology. Rheum Dis Clin North Am 2003; 29: 23954.
  • 4
    Ioannidis JP, Vlachoyiannopoulos PG, Haidich AB, Medsger TA Jr, Lucas M, Michet CJ, et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005; 118: 210.
  • 5
    Clements PJ, Wong WK, Hurwitz EL, Furst DE, Mayes M, White B, et al. Correlates of the Disability Index of the Health Assessment Questionnaire: a measure of functional impairment in systemic sclerosis. Arthritis Rheum 1999; 42: 237280.
  • 6
    Poole JL, Steen VD. The use of the Health Assessment Questionnaire (HAQ) to determine physical disability in systemic sclerosis. Arthritis Care Res 1991; 4: 2731.
  • 7
    Bernatsky S, Hudson M, Panopalis P, Clarke AE, Pope J, Leclercq S, et al. The cost of systemic sclerosis. Arthritis Rheum 2009; 61: 11923.
  • 8
    Wilson L. Cost-of-illness of scleroderma: the case for rare diseases. Semin Arthritis Rheum 1997; 27: 7384.
  • 9
    Danieli E, Airo P, Bettoni L, Cinquini M, Antonioli CM, Cavazzana I, et al. Health-related quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol 2005; 24: 4854.
  • 10
    Hudson M, Steele R, Taillefer S, Baron M, and the Canadian Scleroderma Research Group. Quality of life in systemic sclerosis: psychometric properties of the World Health Organization Disability Assessment Schedule II. Arthritis Rheum 2008; 59: 2708.
  • 11
    Sokka T. Assessment of pain in patients with rheumatic diseases. Best Pract Res Clin Rheumatol 2003; 17: 42749.
  • 12
    Heiberg T, Kvien TK. Preferences for improved health examined in 1,024 patients with rheumatoid arthritis: pain has highest priority. Arthritis Rheum 2002; 47: 3917.
  • 13
    Benrud-Larson LM, Haythornthwaite JA, Heinberg LJ, Boling C, Reed J, White B, et al. The impact of pain and symptoms of depression in scleroderma. Pain 2002; 95: 26775.
  • 14
    Georges C, Chassany O, Toledano C, Mouthon L, Tiev K, Meyer O, et al. Impact of pain in health related quality of life of patients with systemic sclerosis. Rheumatology (Oxford) 2006; 45: 1298302.
  • 15
    Haythornthwaite JA, Heinberg LJ, McGuire L. Psychologic factors in scleroderma. Rheum Dis Clin North Am 2003; 29: 42739.
  • 16
    Hyphantis TN, Tsifetaki N, Siafaka V, Voulgari PV, Pappa C, Bai M, et al. The impact of psychological functioning upon systemic sclerosis patients' quality of life. Semin Arthritis Rheum 2007; 37: 8192.
  • 17
    Malcarne VL, Greenbergs HL. Psychological adjustment to systemic sclerosis. Arthritis Care Res 1996; 9: 519.
  • 18
    Malcarne VL, Hansdottir I, McKinney A, Upchurch R, Greenbergs HL, Henstorf GH, et al. Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis. J Rheumatol 2007; 34: 35967.
  • 19
    Richards HL, Herrick AL, Griffin K, Gwilliam PD, Loukes J, Fortune DG. Systemic sclerosis: patients' perceptions of their condition. Arthritis Rheum 2003; 49: 68996.
  • 20
    Suarez-Almazor ME, Kallen MA, Roundtree AK, Mayes M. Disease and symptom burden in systemic sclerosis: a patient perspective. J Rheumatol 2007; 34: 171826.
  • 21
    Hudson M, Thombs BD, Steele R, Watterson R, Taillefer S, Baron M, and the Canadian Scleroderma Research Group. Clinical correlates of quality of life in systemic sclerosis measured with the World Health Organization Disability Assessment Schedule II. Arthritis Rheum 2008; 59: 27984.
  • 22
    Johnson SR, Gladman DD, Schentag CT, Lee P. Quality of life and functional status in systemic sclerosis compared to other rheumatic diseases. J Rheumatol 2006; 33: 111722.
  • 23
    Del Rosso A, Boldrini M, D'Agostino D, Placidi GP, Scarpato A, Pignone A, et al. Health-related quality of life in systemic sclerosis as measured by the Short Form 36: relationship with clinical and biologic markers. Arthritis Rheum 2004; 51: 47581.
  • 24
    Rannou F, Poiraudeau S, Berezne A, Baubet T, Le-Guern V, Cabane J, et al. Assessing disability and quality of life in systemic sclerosis: construct validities of the Cochin Hand Function Scale, Health Assessment Questionnaire (HAQ), Systemic Sclerosis HAQ, and Medical Outcomes Study 36-item Short Form Health Survey. Arthritis Rheum 2007; 57: 94102.
  • 25
    Merkel PA, Herlyn K, Martin RW, Anderson JJ, Mayes MD, Bell P, et al, for the Scleroderma Clinical Trials Consortium. Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon. Arthritis Rheum 2002; 46: 241020.
  • 26
    Harrell FE Jr. Regression modelling strategies with applications to linear models, logistic regression, and survival analysis. New York: Springer-Verlag; 2001.
  • 27
    LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 2025.
  • 28
    Kahaleh MB, Sultany GL, Smith EA, Huffstutter JE, Loadholt CB, LeRoy EC. A modified scleroderma skin scoring method. Clin Exp Rheumatol 1986; 4: 3679.
  • 29
    Merkel PA, Clements PJ, Reveille JD, Suarez-Almazor ME, Valentini G, Furst DE. Current status of outcome measure development for clinical trials in systemic sclerosis: report from OMERACT 6. J Rheumatol 2003; 30: 163047.
  • 30
    Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol 1999; 26: 215967.
  • 31
    Fuchs HA, Brooks RH, Callahan LF, Pincus T. A simplified twenty-eight–joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum 1989; 32: 5317.
  • 32
    Khanna D, Hays RD, Park GS, Braun-Moscovici Y, Mayes MD, McNearney TA, et al. Development of a preliminary scleroderma gastrointestinal tract 1.0 quality of life instrument. Arthritis Rheum 2007; 57: 12806.
  • 33
    Radloff L. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385401.
  • 34
    Thombs BD, Hudson M, Schieir O, Taillefer SS, Baron M, and the Canadian Scleroderma Research Group. Reliability and validity of the Center for Epidemiologic Studies Depression Scale in patients with systemic sclerosis. Arthritis Rheum 2008; 59: 43843.
  • 35
    Furst D, Khanna D, Matucci-Cerinic M, Clements P, Steen V, Pope J, et al. Systemic sclerosis: continuing progress in developing clinical measures of response. J Rheumatol 2007; 34: 1194200.
  • 36
    Van Tubergen A, Debats I, Ryser L, Londono J, Burgos-Vargas R, Cardiel MH, et al. Use of a numerical rating scale as an answer modality in ankylosing spondylitis–specific questionnaires. Arthritis Rheum 2002; 47: 2428.
  • 37
    Ferraz MB, Quaresma MR, Aquino LR, Atra E, Tugwell P, Goldsmith CH. Reliability of pain scales in the assessment of literate and illiterate patients with rheumatoid arthritis. J Rheumatol 1990; 17: 10224.
  • 38
    Chow E, Doyle M, Li K, Bradley N, Harris K, Hruby G, et al. Mild, moderate, or severe pain categorized by patients with cancer with bone metastases. J Palliat Med 2006; 9: 8504.
  • 39
    Salaffi F, Stancati A, Silvestri CA, Ciapetti A, Grassi W. Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale. Eur J Pain 2004; 8: 28391.
  • 40
    Hedges LV. Estimation of effect size from a series of independent experiments. Psychol Bull 1982; 92: 4909.
  • 41
    Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale (NJ): Lawrence Earlbaum; 1988.
  • 42
    Greenland S. Invited commentary: variable selection versus shrinkage in the control of multiple confounders. Am J Epidemiol 2008; 167: 5239.
  • 43
    Van Buuren S, Oudshoorn K. Flexible multivariate imputation by MICE: report PG/VGZ/99.054. Leiden (The Netherlands): TNO Prevention and Health; 1999.
  • 44
    Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 45
    Carreira PE. 'Quality of pain' in systemic sclerosis [editorial]. Rheumatology (Oxford) 2006; 45: 11856.
  • 46
    Fitzcharles MA, Dacosta D, Ware MA, Shir Y. Patient barriers to pain management may contribute to poor pain control in rheumatoid arthritis. J Pain 2009; 10: 3005.
  • 47
    Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001; 94: 14958.
  • 48
    Gazi H, Pope JE, Clements P, Medsger TA, Martin RW, Merkel PA, et al. Outcome measurements in scleroderma: results from a Delphi exercise. J Rheumatol 2007; 34: 5019.
  • 49
    Fitzcharles MA, Shir Y. New concepts in rheumatic pain. Rheum Dis Clin North Am 2008; 34: 26783.
  • 50
    Kidd BL, Urban LA. Mechanisms of inflammatory pain. Br J Anaesth 2001; 87: 311.
  • 51
    Keefe FJ, Somers TJ, Martire LM. Psychologic interventions and lifestyle modifications for arthritis pain management. Rheum Dis Clin North Am 2008; 34: 35168.